文献速递肿瘤 PET/CT神经核医学

脑膜瘤下一代PET/CT成像:新型SSTR靶向肽[18F]SiTATE的首批临床经验

Next-generation PET/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-06-26

纳入107例患者共117次[18F]SiTATE PET/CT扫描,分析231个脑膜瘤病灶与61个非脑膜瘤病灶。脑膜瘤SUVmax 11.6±10.6显著高于非脑膜瘤病灶4.0±3.3(p<0.001)。25.6%(59/231)病灶为既往标准影像未报告,40.3%见部分骨外延伸、14.7%以骨内延伸为主。

要点

  • 脑膜瘤[18F]SiTATE摄取SUVmax 11.6±10.6,显著高于非脑膜瘤病灶4.0±3.3(p<0.001)。
  • 健康脑组织SUVmean最低(0.06±0.04),垂体最高(9.8±4.6),p<0.001。
  • 25.6%(59/231)脑膜瘤病灶为既往标准影像未报告。

核心结论

  • [18F]SiTATE在脑膜瘤中相较健康组织和非脑膜瘤病灶提供极高对比度,带来对既往未知脑膜瘤部位和骨受累的高检出率。
  • 考虑18F标记相较68Ga标记化合物的物流优势(如更长半衰期和大批量生产),[18F]SiTATE有潜力推动SSTR靶向成像在神经肿瘤领域的广泛使用。

研究设计与样本

  • 纳入已知或疑似脑膜瘤并接受[18F]SiTATE PET/CT的患者,共107例患者117次扫描。
  • 脑膜瘤病灶用50%等轮廓容积感兴趣区(VOI)、健康器官用球形VOI评估摄取强度(SUV)。
  • 同时评估PET/CT上的经骨延伸。

主要发现

  • 共分析231个脑膜瘤病灶和61个非脑膜瘤病灶(如治疗后改变)。
  • 生理性摄取最低为健康脑组织,其次为骨髓、腮腺和垂体(SUVmean 0.06±0.04 vs 1.4±0.9 vs 1.6±1.0 vs 9.8±4.6;p<0.001)。
  • 脑膜瘤摄取显著高于非脑膜瘤病灶(SUVmax 11.6±10.6 vs 4.0±3.3,p<0.001)。
  • 93/231(40.3%)脑膜瘤见部分经骨延伸,34/231(14.7%)以骨内延伸为主。
  • 59/231(25.6%)PET/CT发现的脑膜瘤病灶既往标准影像未报告。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Somatostatin-receptor (SSTR)-targeted PET/CT provides important clinical information in addition to standard imaging in meningioma patients. [18F]SiTATE is a novel, 18F-labeled SSTR-targeting peptide with superior imaging properties according to preliminary data. We provide the first [18F]SiTATE PET/CT data of a large cohort of meningioma patients. METHODS: Patients with known or suspected meningioma undergoing [18F]SiTATE PET/CT were included. Uptake intensity (SUV) of meningiomas, non-meningioma lesions, and healthy organs were assessed using a 50% isocontour volume of interest (VOI) or a spherical VOI, respectively. Also, trans-osseous extension on PET/CT was assessed. RESULTS: A total of 107 patients with 117 [18F]SiTATE PET/CT scans were included. Overall, 231 meningioma lesions and 61 non-meningioma lesions (e.g., post-therapeutic changes) were analyzed. Physiological uptake was lowest in healthy brain tissue, followed by bone marrow, parotid, and pituitary (SUVmean 0.06 ± 0.04 vs. 1.4 ± 0.9 vs. 1.6 ± 1.0 vs. 9.8 ± 4.6; p < 0.001). Meningiomas showed significantly higher uptake than non-meningioma lesions (SUVmax 11.6 ± 10.6 vs. 4.0 ± 3.3, p < 0.001). Meningiomas showed significantly higher uptake than non-meningioma lesions (SUVmax 11.6±10.6 vs. 4.0±3.3, p<0.001). 93/231 (40.3%) meningiomas showed partial trans-osseous extension and 34/231 (14.7%) predominant intra-osseous extension. 59/231 (25.6%) meningioma lesions found on PET/CT had not been reported on previous standard imaging. CONCLUSION: This is the first PET/CT study using an 18F-labeled SSTR-ligand in meningioma patients: [18F]SiTATE provides extraordinary contrast in meningioma compared to healthy tissue and non-meningioma lesions, which leads to a high detection rate of so far unknown meningioma sites and osseous involvement. Having in mind the advantageous logistic features of 18F-labeled compared to 68Ga-labeled compounds (e.g., longer half-life and large-badge production), [18F]SiTATE has the potential to foster a widespread use of SSTR-targeted imaging in neuro-oncology.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Unterrainer M, Kunte SC, Unterrainer LM, et al. Next-generation PET/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE. Eur J Nucl Med Mol Imaging. 2023. PMID: 37358620. doi:10.1007/s00259-023-06315-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。